Synapsoft logo
AI Insights from Disclosures
Searching...
SunBio, Inc. 067370
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
SunBio, Inc. currently operates in the following fields: the neutropenia treatment PEG-filgrastim; the dry mouth treatment MucoPEG; R&D of the artificial blood SBX; R&D of secondary battery electrolytes; and the production and sale of PEG derivatives. The neutropenia treatment PEG-filgrastim is currently sold in the EU, Canada, Australia, India, and other regions, and the company produces mPEG-PAL, a PEG derivative used in the production of the neutropenia treatment, and exports it to Intas Pharma, the finished product manufacturer. The company also receives royalties from sales of the finished product.
Representative Director No Gwang
Founded June 10, 1997
Corporation Type KOSDAQ
Industry Classification Manufacture of medicaments
Corporate number 11011-1424243
Business number 213-86-32344
Phone Number 032-812-5467
Fax Number 032-811-5430
Website www.sunbio.com
Company Address 129 Eunbong-ro, Namdong-gu, Incheon
Products & Services

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant